Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
about
Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population.Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
P2860
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@ast
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@en
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@nl
type
label
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@ast
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@en
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@nl
prefLabel
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@ast
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@en
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@nl
P2093
P2860
P50
P356
P1433
P1476
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW
@en
P2093
Dawn C Schwenke
Devjit Tripathy
Frankie B Stentz
MaryAnn Banerji
Nicolas Musi
Peter D Reaven
Robert E Ratner
Robert R Henry
Stephen C Clement
Sunder Mudaliar
P2860
P304
P356
10.2337/DC13-1745
P407
P577
2014-04-04T00:00:00Z